Dr Reddys Laboratories (RDY) Beginning Cash Balance (2025 - 2026)
Dr Reddys Laboratories (RDY) posted Beginning Cash Balance of $162.3 million for Q2 2026, down 4.8% on a QoQ basis from $170.5 million in Q2 2025, and down 4.8% year-over-year from $170.5 million in Q2 2025.
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Beginning Cash Balance (2025 - 2026) Analysis & Trends
Dr Reddys Laboratories has reported Beginning Cash Balance for 2 years, with the latest figure at $162.3 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.32 Bn | 38.67 Bn | 2.15 Bn |
| 2 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.76 Bn | 9.59 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.43 Bn | 5.30 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 461.13 Mn | 2.10 Bn |
| 6 | Alvotech | 1.54 Bn | 1.40 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.01 Bn | 722.42 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 173.87 Mn | 173.87 Mn | - |